Biocept Reports First Quarter 2021 Financial Results

Biocept Reports First Quarter 2021 Financial Results

  • Revenues of $17.8 million were driven by RT-PCR COVID-19 testing
  • Initiated full commercial launch of CNSide™ cerebrospinal fluid assay for diagnosing and managing patients with metastatic cancer involving the central nervous system
  • Received approximately 390,000 COVID-19 samples since June 2020
  • Hosted KOL webinar with leading neuro-oncologists discussing their use of CNSide and its importance in clinical decisions that affect patient outcomes

Conference call begins at 4:30 p.m. Eastern time today

SAN DIEGO–(BUSINESS WIRE)–Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2021 and provides a business update.

“We are reporting profitability for the second consecutive quarter on revenues of $17.8 million, as our dedicated Biocept team continued to serve our community with COVID-19 RT-PCR testing featuring exceptional customer service and rapid turnaround times,” said Michael Nall, Biocept’s President and CEO. “These outstanding financial results support further advancements with our core oncology business and more specifically our focus on neuro-oncology as we build for a strong long-term future.

“The full commercial launch of CNSide, our cerebrospinal fluid assay detecting tumor cells and molecular biomarkers, is transformational for Biocept,” he added. “We developed CNSide to address a high unmet medical need by providing diagnostic testing that we believe exceeds the capabilities of the current standard of care, CSF cytology. In early studies, CNSide has shown better sensitivity than CSF cytology in detecting patients with metastatic cancer involving the central nervous system. CNSide has the added advantage of providing quantitative results, which is showing promise in assessing patient response to therapy and monitoring patients for minimal residual disease.

“We are pursuing a clinical strategy to support CNSide as the new standard-of-care diagnostic for cancer that has metastasized to the central nervous system. We also are expanding our reach to neuro-oncologists, medical oncologists and other physicians to build upon the positive reception our assay has received from early adopters. Following our soft launch in early 2020, we have seen CNSide orders increase quarterly with many physicians ordering repeatedly. We recently hosted a highly informative webinar in which three neuro-oncology leaders using our CNSide assay in their practices cited multiple case studies with favorable patient outcomes,” he added. “This is an exciting opportunity for Biocept to help patients with breast and lung cancers that have metastasized to the central nervous system—a U.S. market we estimate at more than $1 billion annually.

“I’m exceptionally proud of the Biocept team for stepping up to address the pressing public health need for COVID-19 testing,” said Mr. Nall. “Since we began offering this service in 2020, we have received approximately 390,000 samples, including about 140,000 samples during the first quarter. We recently announced a partnership to make our service available to all 116 California community colleges including their 2.1 million students, as well as faculty and staff. We expect COVID-19 testing will continue to be an important component of our business and provide meaningful revenues throughout 2021, noting our expectations might change as the pandemic evolves.”

First Quarter 2021 and Recent Highlights

Commercial Launches, Developments and Agreements

Oncology

  • Initiated the full commercial launch of CNSide, Biocept’s cerebrospinal fluid assay that offers a timely and accurate method to diagnose patients with lung and breast cancer that has metastasized to the central nervous system, along with the ability to identify actionable biomarkers and assess a patient’s response to therapy. CNSide is based on Biocept’s proprietary quantitative tumor cell capture and detection method paired with assays to identify actionable molecular treatment targets.
  • Established a collaboration with Protean BioDiagnostics, an independent pathology laboratory, to evaluate the ability of the novel Target Selector™ research use only (RUO) kits to determine EGFR status in patients with non-small cell lung cancer (NSCLC) comparing circulating tumor DNA (ctDNA) from blood with formalin-fixed paraformaldehyde embedded (FFPE) tissue samples. Protean BioDiagnostics also expects to validate the analytical performance of a laboratory developed test (LDT) based on Biocept’s EGFR assay test kit in accordance with the requirements of the College of American Pathologists (CAP) validation process.

COVID-19

  • Partnered with the Foundation for California Community Colleges to make Biocept’s COVID-19 testing available for purchase and use with more than 2.1 million students, as well as faculty and staff through the Foundation’s CollegeBuys program. The availability of COVID-19 testing is expected to provide information needed to help protect the safety of campus populations and reduce the spread of the SARS-CoV-2 virus as students return to campus from the current remote learning environment.
  • Received approximately 390,000 samples for COVID-19 RT-PCR testing at Biocept’s high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory since beginning to offer this testing in 2020. The lab is using Thermo Fisher Scientific’s FDA-approved for EUA testing TaqPath™ molecular diagnostic platform and kit. The vast majority of test results to date have been reported to healthcare providers within 48 hours of sample receipt.
  • Entered into development and supply agreements with Aegea Biotechnologies following success under Biocept’s first agreement with Aegea to develop a new, highly sensitive quantitative PCR-based COVID-19 assay. The new assay utilizes the patented Switch-Blocker™ technology, which is also used in Biocept’s Target Selector assays. Under the supply agreement, Aegea is supplying the COVID-19 assay kit for validation in Biocept’s lab. Following validation, Biocept intends to commercialize an LDT. The assay is designed for quantitative monitoring of viral RNA load to better assist healthcare providers in screening and managing patients.

Clinical Study

  • Announced plan to initiate a clinical validation study, the 4C trial, evaluating the performance of the CNSide assay compared with current standard of care, which includes imaging, CSF cytology and clinical evaluation of patients with suspected cancer metastasis involving the central nervous system. This study and our planned application for FDA breakthrough device designation will support the Company’s efforts to introduce an FDA-cleared class II IVD product.

Industry Presentations and Publication

  • Hosted a neuro-oncology webinar discussing CNSide for the diagnosis of cancer involving the central nervous system. The webinar featured a technology overview and leading neuro-oncologists citing case studies using the CNSide assay with subsequent favorable patient outcomes.
  • Presented a poster with colleagues from NeoGenomics Laboratories (Nasdaq: NEO) at the Molecular Med Tri-Con Virtual Conference showing Biocept’s Target Selector molecular assay kit detected mutations in up to 50% of tissue biopsy specimens from patients diagnosed with NSCLC that were deemed quantity not sufficient (QNS) due to a lack of tissue to perform testing. The assay was used to evaluate the presence of several key EGFR and KRAS mutations in FFPE biopsy samples that had inadequate tumor for next-generation sequencing (NGS) analysis.

First Quarter Financial Results

Revenues for the first quarter of 2021 were $17.8 million, compared with $1.4 million for the first quarter of 2020, with the increase attributable to RT-PCR COVID-19 testing. Revenues for the first quarter of 2021 included $17.7 million in commercial test revenue, which is comprised of $16.8 million attributable to RT-PCR COVID-19 testing, $39,000 in development services test revenue and $62,000 in revenue from distributed products, Target Selector RUO kits, CEE-Sure® blood collection tubes and payments from Aegea Biotechnologies for services associated with the development of a COVID-19 assay. Revenues for the first quarter of 2020 included $1.3 million in commercial test revenue, $60,000 in development services test revenue and $69,000 in revenue for Target Selector RUO kits and CEE-Sure blood collection tubes.

Biocept accessioned 145,110 total samples during the first quarter of 2021, compared with 1,306 total samples during the first quarter of 2020. The Company accessioned 144,932 commercial billable samples during the first quarter of 2021, compared with 985 commercial billable samples during the first quarter of 2020. The increase in total and commercial billable samples was primarily attributable to COVID-19 testing.

Cost of revenues for the first quarter of 2021 was $9.0 million, compared with $2.9 million for the first quarter of 2020, with the increase primarily due to COVID-19-related collection kits and consumable expenses. Research and development (R&D) expenses for the first quarter of 2021 were $1.0 million, compared with $1.3 million for the first quarter of 2020, with the decrease primarily attributable to lower facilities costs and cost of revenue allocations to R&D. General and administrative (G&A) expenses for the first quarter of 2021 were $3.1 million, compared with $1.9 million for the first quarter of 2020, with the increase primarily due to headcount additions and other expenses related to COVID-19 testing. Sales and marketing expenses for the first quarter of 2021 were $1.9 million, compared with $1.5 million for the first quarter of 2020, with the increase resulting from higher sales commissions due to higher revenues.

Operating income for the first quarter of 2021 was $2.7 million, versus an operating loss of $6.2 million for the first quarter of 2020.

Other expense, net for the first quarter of 2021 was $65,000, compared with other expense, net for the first quarter of 2020 of $2.2 million, with the decrease mainly due to $2.1 million in warrant inducement expense in the first quarter of 2020.

Net income attributable to common shareholders for the first quarter of 2021 was $2.6 million, or $0.19 per diluted share on 13.7 million weighted-average shares outstanding. This compares with a net loss attributable to common shareholders for the first quarter of 2020 of $8.3 million, or $1.06 per diluted share on 7.9 million weighted-average shares outstanding. The change in outstanding share count reflects the 1-for-10 reverse split of common stock effected in September 2020.

Biocept reported cash and cash equivalents as of March 31, 2021 of $14.2 million, compared with $14.4 million as of December 31, 2020.

Conference Call and Webcast

Biocept will hold a conference call today at 4:30 p.m. Eastern time to discuss these results and answer questions. The conference call can be accessed by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers. A live webcast of the conference call will be available on the investor relations page of the Company’s website at http://ir.biocept.com/events.cfm.

A replay of the call will be available for 48 hours following its conclusion and can be accessed by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers or (412) 317-0088 for other international callers. Please use event passcode 10155314. A replay of the webcast will be available for 90 days.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

Forward-Looking Statements Disclaimer Statement

This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project,” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to the ability of our assays to uniquely address a high unmet clinical need by identifying metastatic progression of cancer to the central nervous system and brain, our ability to establish our assays as the standard of care in diagnosing cancer with central nervous system involvement, the extent to which COVID-19 testing will continue to be an important component of our business and provide meaningful revenues throughout 2021, and our ability to validate and commercialize the COVID-19 assay kit co-developed with Aegea Biotechnologies, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at http://www.sec.gov/.

BIOCEPT, INC.

CONDENSED BALANCE SHEETS

 

 

 

 

 

 

 

December 31,

 

March 31,

 

2020

 

2021

 

 

 

 

 

(unaudited)

ASSETS
Cash $

14,367,942

$

14,197,547

Accounts receivable, net

14,144,911

17,143,572

Inventories, net

1,929,624

3,258,594

Prepaid expenses and other current assets

2,151,527

697,724

TOTAL CURRENT ASSETS

32,594,004

35,297,437

FIXED ASSETS, NET

2,317,616

2,095,704

LEASE RIGHT-OF-USE ASSETS

12,114,058

12,466,926

OTHER NON-CURRENT ASSETS

425,908

438,776

TOTAL ASSETS $

47,451,586

$

50,298,843

LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES, NET $

12,494,253

$

11,913,007

NON-CURRENT LIABILITIES, NET

11,264,911

11,614,609

TOTAL LIABILITIES

23,759,164

23,527,616

SHAREHOLDERS’ EQUITY

23,692,422

26,771,227

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $

47,451,586

$

50,298,843

BIOCEPT, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

 

 

 

 

 

 

 

For the three months ended March 31,

 

2020

 

2021

 

 

(unaudited)

 

(unaudited)

 

 
NET REVENUES $

1,446,549

 

$

17,756,190

 

COSTS AND EXPENSES
Cost of revenues

$

2,946,858

 

$

9,005,856

 

Research and development expenses

1,312,676

 

1,042,725

 

General and administrative expenses

1,904,433

 

3,119,804

 

Sales and marketing expenses

1,465,115

 

1,923,272

 

Total costs and expenses

7,629,082

 

15,091,657

 

(LOSS)/INCOME FROM OPERATIONS

(6,182,533

)

2,664,533

 

INTEREST AND OTHER INCOME/(EXPENSE), NET

(2,158,805

)

(65,241

)

(LOSS)/INCOME BEFORE INCOME TAXES

(8,341,338

)

2,599,292

 

INCOME TAXES

 

 

NET (LOSS)/INCOME AND COMPREHENSIVE LOSS $

(8,341,338

)

$

2,599,292

 

Deemed dividend related to warrants down round provision

(2,774

)

 

NET (LOSS)/INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS

(8,344,112

)

2,599,292

 

NET (LOSS)/INCOME PER SHARE
– Basic $

(1.06

)

$

0.19

 

– Diluted $

(1.06

)

$

0.19

 

WEIGHTED AVG NUMBER OF SHARES OUTSTANDING
– Basic

7,899,991

 

13,400,007

 

– Diluted

7,899,991

 

13,667,716

 

 

Investor Contact:

LHA Investor Relations

Jody Cain

[email protected], (310) 691-7100

Media Contact:

Sampson PR Group

Andrea Sampson

[email protected], (562) 304-0301

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Health Oncology Other Health

MEDIA:

Logo
Logo

Gaia to Participate in Upcoming Virtual Investor Conferences

BOULDER, Colo., May 12, 2021 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA) (“Gaia” and/or the “Company”), a conscious media and community company, is scheduled to participate in the following virtual investor conferences:

  • On Monday, May 17th, the Company will be attending the 16th Annual Needham Virtual Technology & Media Conference.
  • On Thursday, May 20th, the Company will be presenting at the Sidoti Virtual Microcap Conference at 11:30 a.m. ET. The presentation will be broadcast live and available for replay here and via the investor relations section of the company’s website at www.gaia.com.
  • On Wednesday, June 16th, and Thursday, June 17th, the Company will be attending the East Coast IDEAS Virtual Conference.

To receive additional information or to schedule a one-on-one meeting at these conferences, please contact your conference representative or Gaia’s investor relations team at [email protected].

About Gaia

Gaia is a member-supported global video streaming service and community that produces and curates conscious media through four primary channels—Seeking Truth, Transformation, Alternative Healing and Yoga—to its members in 185 countries. Gaia’s library includes approximately 8,000 titles, over 80% of which is exclusive to Gaia, and approximately 80% of the views are generated by content produced or owned by Gaia. Gaia is available on Apple TV, iOS, Android, Roku, Chromecast, and sold through Amazon Prime Video and Comcast Xfinity. For more information about Gaia, visit www.gaia.com.

Company Contact:

Paul Tarell
Chief Financial Officer
Gaia, Inc.
[email protected]

Investor Relations:

Gateway Investor Relations
Cody Slach
(949) 574-3860
[email protected]



SkyWater Technology to Webcast First Quarter Fiscal 2021 Financial Results

SkyWater Technology to Webcast First Quarter Fiscal 2021 Financial Results

BLOOMINGTON, Minn.–(BUSINESS WIRE)–SkyWater Technology, (NASDAQ: SKYT) today announced that it intends to report first quarter fiscal 2021 financial results for the period ended April 4, 2021, following the close of the market on Tuesday, May 18, 2021. The following morning, management will host a webcast to discuss its business and financial results.

SkyWater Technology First Quarter Fiscal 2021 Earnings Webcast

When: Wednesday, May 19, 2021

Time: 9:00 a.m. CT (10:00 a.m. ET)

Live Webcast: https://ir.skywatertechnology.com

An archived webcast will be available on SkyWater Technology’s Investor Relations page, https://ir.skywatertechnology.com.

About SkyWater Technology

SkyWater is a U.S.-owned and U.S.-based pure play semiconductor foundry and is a DOD-accredited Trusted supplier, specializing in custom technology development services, volume manufacturing, and advanced packaging capabilities. Through its Technology Foundry model, SkyWater’s world-class operations in Bloomington, Minnesota and Kissimmee, Florida provide unique processing capabilities to enable quality production and advanced packaging for mixed-signal CMOS, power, rad-hard and ROIC solutions. SkyWater’s Advanced Technology Services empower development of superconducting and 3D ICs, along with carbon nanotube, photonic and MEMS devices. The company serves customers in growing markets such as aerospace & defense, automotive, biomedical, cloud & computing, consumer, industrial and IoT. Please visit www.skywatertechnology.com/ for more information.

Source String: SkyWater Technology

SKYT-IR

SkyWater Investor Contact: Heather Davis | [email protected]

SkyWater Media Contact: Lauri Julian| 949.280.5602 | [email protected]

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Technology Hardware Semiconductor

MEDIA:

Logo
Logo

Nextech AR Solutions Corp. Reports Record Q1 2021 Results

Nextech AR Solutions Corp. Reports Record Q1 2021 Results

LiveX Platform Expected to Generate Annual Cost Savings of $6 Million

VANCOUVER, British Columbia–(BUSINESS WIRE)–Nextech AR Solutions Corp. (“Nextech” or the “Company”) (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29) announces its financial results for the first quarter 2021 ending March 31st, 2021 and a operational Nextech AR LiveX update. Subsequently, Nextech will host a conference call to discuss the first quarter results and operations update on May 12th, 2021 at 5:30 p.m. Eastern Time.

Q1 Financial highlights:

  • Revenue for the three months ended March 31st, 2021 was $7.7 million an increase of over 200% compared to the three months ended March 31st, 2020 of $2.5 million.
  • Gross profit for the three months ended March 31st, 2021 was $3.3 million an increase of over 280% compared to the three months ended March 31st, 2020 of $1.4 million.
  • Total Bookings for the three months ended March 31st, 2021 was $2.2 million an increase of over 4,700% compared to the three months ended March 31st, 2020 of $0.5 million.

LiveX Operational Update:

Nextech is pleased to announce that its next-generation digital experience platform Nextech AR LiveX is now live. LiveX is a highly scalable all-in-one streaming platform for creators, corporate events, livestreaming, music, NFTs which is AR enhanced and advertising enabled.The platform is also being intergraded with Shopify to allow for seamless ecommerce and merchandise sales.

As a result of the successful launch of LiveX, the Companyhas committed all current and future events to be hosted and monetized on LiveX Platform. The LiveX Platform has demonstrated the following advantages:

  • With LiveX our Events are designed 10X faster allowing for cost savings and scale.
  • Multiple monetization options: ads, ticketing, merch sales, event sales and NFT auctions.
  • Better user functionality and design resulting in an improved attendee experience.
  • Reduction in the cost-to-serve per event, yielding a greater gross profit margin with the additional benefit of recurring revenues from monthly and annual subscriptions.

Transitioning all events to our LiveX platform will save the Company approximately $6.0 million annually relating to streamlining the engineering, development and support costs associated with earlier versions of the technology platform.

Nextech AR LiveX has the potential for further delivery efficiencies and related costs benefits through Q3 with the release of LiveX 2.0, featuring self-serve.

“Our Q1 2021 record results are a testament to the success of our diversified business model and our unique value proposition; offering Augmented Reality technology in everything that we do. Our business is growing rapidly through AR innovation and our DXP platform LiveX. LiveX is built for scale for enterprise clients targeting key verticals like education, entertainment, events, retail, medical and marketplaces. We see this as the digital experience platform of the future, today,” said Evan Gappelberg CEO and Director.

NexTech AR Solutions Corp.

Condensed Consolidated Interim Statements of Financial Position

(Expressed in Canadian dollars)

(Unaudited)

 

March 31, 2021

December 31, 2020

Assets
 
Current assets
Cash

$

7,900,016

 

$

10,684,952

 

Digital Assets

 

 

 

2,546,035

 

Receivables

 

2,095,953

 

 

1,312,548

 

Contract Asset

 

360,060

 

 

244,478

 

Prepaid expenses

 

1,744,576

 

 

1,354,369

 

Inventory

 

4,673,895

 

 

3,211,675

 

 

16,774,500

 

 

19,354,057

 

Non-current assets
Equipment

 

337,036

 

 

300,558

 

Right-of-use asset

 

992,298

 

 

1,034,724

 

Intangible assets

 

3,090,162

 

 

3,500,041

 

Goodwill

 

4,847,750

 

 

4,886,513

 

Total assets

$

26,041,746

 

$

29,075,893

 

 
Liabilities and Shareholders’ Equity
 
Current liabilities
Accounts payable and accrued liabilities

$

3,976,397

 

$

2,527,437

 

Deferred revenue

 

1,193,069

 

 

383,022

 

Lease liability

 

147,750

 

 

150,662

 

Contingent consideration

 

2,489,557

 

 

2,717,859

 

 

7,806,773

 

 

5,778,980

 

Non-current liabilities
Lease liability

 

836,323

 

 

877,978

 

Total liabilities

 

8,643,096

 

 

6,656,958

 

 
Shareholders’ Equity
Share capital

 

43,775,485

 

 

41,968,520

 

Reserves

 

9,113,625

 

 

6,757,098

 

Deficit

 

(35,490,460

)

 

(26,306,683

)

 

17,398,650

 

 

22,418,935

 

Total liabilities and shareholders’ equity

$

26,041,746

 

$

29,075,893

 

NexTech AR Solutions Corp.

Condensed Consolidated Interim Statements of Comprehensive Loss

(Expressed in Canadian dollars)

(Unaudited)

 

Three months ended

Three months ended

March 31, 2021

March 31, 2020

Revenue

$

7,726,703

 

$

2,491,985

 

Cost of sales

 

(4,412,278

)

 

(1,144,136

)

Gross profit

 

3,314,425

 

 

1,347,849

 

 
Operating expenses:
Sales and marketing

 

4,640,087

 

 

1,418,833

 

General and administrative

 

3,747,723

 

 

709,427

 

Research and development

 

1,793,479

 

 

239,193

 

 

10,181,289

 

 

2,367,453

 

 
Other income (expense)
Stock-based compensation

 

2,402,628

 

 

268,275

 

Amortization

 

380,220

 

 

88,253

 

Gain on digital assets

 

(219,321

)

 

 

Depreciation

 

27,950

 

 

9,849

 

Foreign exchange gain

 

(274,564

)

 

1,694

 

Financing expense

 

 

 

 

 

2,316,913

 

 

368,071

 

 
Loss before income taxes

 

(9,183,777

)

 

(1,387,675

)

Deferred income tax recovery

 

 

 

24,239

 

Net loss

$

(9,183,777

)

$

(1,363,436

)

 
Other comprehensive income (loss)
Exchange differences on translating foreign operations

 

(52,401

)

 

488,316

 

Total comprehensive loss

$

(9,236,178

)

$

(875,120

)

 
 
Loss per common share
Basic and diluted loss per common share

 

(0.12

)

 

(0.02

)

Weighted average number of common shares outstanding

Basic and diluted

 

77,489,618

 

 

61,378,508

 

NexTech AR Solutions Corp.

Condensed Consolidated Interim Statements of Cash Flows

(Expressed in Canadian dollars)

(Unaudited)

 

Three months ended

Three months ended

March 31, 2021

March 31, 2020

Cashflows from operating activities
Net loss

$

(9,183,777

)

$

(1,363,436

)

 
Items not affecting cash
Amortization of intangible assets

 

380,220

 

 

88,253

 

Amortization of right to use asset

 

34,311

 

 

 

Gain on sale of bitcoin

 

(219,321

)

 

(24,239

)

Depreciation of property and equipment

 

27,950

 

 

9,849

 

Shares issued to settle related party liability

 

1,299,845

 

 

38,239

 

Stock-based compensation

 

2,402,628

 

 

 

Share-based payments

 

22,156

 

 

650,946

 

Shares issued for exercise of options

 

6,300

 

 

 

 
Changes in non-cash working capital balances
Receivables

 

(783,405

)

 

(217,245

)

Contract Asset

 

(115,582

)

Prepaid expenses

 

(390,207

)

 

(19,075

)

Bitcoin

 

2,546,035

 

 

 

Inventory

 

(1,462,220

)

 

(244,810

)

Accounts payable and accrued liabilities

 

1,448,960

 

 

(325,523

)

Deferred revenue

 

810,047

 

 

 

Net cash used in operating activities

$

(3,176,060

)

$

(1,407,041

)

 
Cashflows from investing activities
Sale of Bitcoin

 

219,321

 

 

 

Purchase of equipment

 

(50,414

)

 

 

Net cash used in investing activities

$

168,907

 

$

 

 
Cashflows from financing activities
Proceeds from exercise of options and warrants

 

486,464

 

 

712,439

 

Payment of lease obligations

 

(44,567

)

 

 

Net cash provided by financing activities

$

441,897

 

$

712,439

 

 
Change in cash during the period

 

(2,565,256

)

 

(694,602

)

Cash, beginning of period

 

10,684,952

 

 

2,849,344

 

Effects of foreign exchange on cash

 

(219,680

)

 

154,914

 

 
Cash, end of period

$

7,900,016

 

$

2,309,656

 

 
Supplemental cash flow information
Taxes paid

 

 

 

 

Interest Paid

 

1,261

 

 

 

Interest received

 

9,298

 

 

 

Conference Call Details:

Date: Wednesday, May 12th, 2021

Time: 5:30 p.m. Eastern Time

Toll Free Dial-In Number: (877) 201-0168

International Dial-In Number: (647) 788-4901

Conference ID: 4288924

Webcast Link: Nextech AR Q1, 2021 Earnings Call

For those unable to join the live event, a recording of the presentation will be posted on the company’s website.

About NexTech AR

NexTech develops and operates augmented reality (“AR”) platforms that transports three-dimensional (“3D”) product visualizations, human holograms and 360° portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.

NexTech focuses on developing AR solutions however most of the Company’s revenues are derived from three e-Commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon.

To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website.

On behalf of the Board of Nextech AR Solutions Corp.

Evan Gappelberg

CEO and Director

Non-IFRS Financial Measures

Total Bookings and Backlog are not defined by and does not have a standardized meaning under International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board. These non-IFRS financial performance measures are defined below. Non-IFRS financial measures are used by management to assess the financial and operational performance of the Company. The Company believes that these non-IFRS financial measure, in addition to conventional measures prepared in accordance with IFRS, enables investors to evaluate the Company’s operating results, underlying performance and prospects in a similar manner to the Company’s management. As there are no standardized methods of calculating these non-IFRS measures, the Company’s approaches may differ from those used by others, and accordingly, the use of these measures may not be directly comparable. Accordingly, this non-IFRS measure is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

Total Bookings: the total dollar value of technology services and license services included in contracts with our customers. ‘Value’ is the total revenue (recognizable or not) associated with each transaction, as opposed to the amount invoiced or recognized as revenue in the period. This information provides the user with information on the performance of our sales efforts in the period as there is a timing difference between when we close a deal and when it is ultimately ‘earned’ as defined in IFRS for revenue due to the term of our contracts and delivery timelines.

Backlog: the estimated unearned portion of technology services and license services in customer contracts that are in process and have not been completed as at the specified date. This includes billed and unbilled amounts within each contract. Since our revenue is recognized as earned, this will translate to total bookings to date less earned revenue recognized on the financial statements. This information provides the user with an estimate of the work expected to be completed and earned in the future at a given point in and is used by management to allocate resources to our revenue delivery team.

Please refer to the Company’s most recent management discussion and analysis for further information and reconciliations for these non-IFRS measures.

Forward-looking Statements

This press release contains forward-looking statements. Please refer to our cautionary language on forward-looking statements and the other matters set forth at the end of this press release. Nextech’s unaudited financial statements for the quarter ending March 31, 2021 and notes thereto (the “financial statements”), and the MD&A are available on our website at www.nextechar.com and are filed on SEDAR at www.sedar.com. All figures are prepared in accordance with International Financial Reporting Standards (IFRS) unless otherwise indicated.

This press release may contain forward-looking information within the meaning of applicable securities laws, which reflects the Company’s current expectations regarding future events, including with respect to the Company’s financial outlook. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Specifically, NexTech’s forecast on Total Bookings is considered forward-looking information. The foregoing demonstrates NexTech’s objectives, which are not forecasts or estimates of its financial position but are based on the implementation of its strategic goals, growth prospects and growth initiatives. Management’s assessments of, and outlook for, Total Bookings set out herein are generally based on the following assumptions: (a) NexTech’s results of operations will continue as expected, (b) the Company will continue effectively execute against its key strategic growth priorities, (c) the Company will continue to retain and grow its existing customer base and market share, (d) the Company will be able to take advantage of future prospects and opportunities, and continue to realize on synergies, (e) there will be no changes in legislative or regulatory matters that negatively impact NexTech’s business, (f) current tax laws will remain in effect and will not be materially changed, (g) economic conditions will remain relatively stable throughout the period, and (h) the industries NexTech operates in will continue to grow consistent with past experience. The Company considers these assumptions to be reasonable in the circumstances, given the time period for such projections and targets. The achievement of target revenue set out above is subject to significant risks including: (a) that the Company will be unable to effectively execute against its key strategic growth priorities and (b) the Company will be unable to continue to retain and grow its existing customer base and market share. These estimates have been prepared by and are the responsibility of management.

Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under “Risk Factors” in the final short form prospectus of the Company dated August 12, 2020. NexTech does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The NEO has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance, or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

Evan Gappelberg

[email protected]

KEYWORDS: United States North America Canada

INDUSTRY KEYWORDS: Data Management Technology Other Technology Audio/Video Software Networks Internet

MEDIA:

Logo
Logo

PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience

PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience

Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing

WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Biosciencefor $260 Million in cash. The transaction is expected to close during the second quarter of 2021.

Nexcelomis a leading, global provider ofautomated cell counting instruments, image cytometry workstations, assays and a variety of cell reagents, consumables, and fit-for-purpose cell counting method selection and development instructions that follow ISO Cell Counting Standards and aid in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines.

Headquartered in Lawrence, Massachusetts, Nexcelom is founder-led, privately held and has approximately 130 employees around the world based in the U.S., the UK and China. Nexcelom’s expected 2021 revenues are approximately $40 Million.

Commenting on the transaction, Prahlad Singh, president and chief executive officer of PerkinElmer said, “We are looking forward to bringing Nexcelom’s expertise and technologies in drug development together with our passion and solutions for drug discovery. This combination will expand our efforts to help academic, government and biopharmaceutical organizations streamline their complete workflows and support efforts to accelerate time to target and time to market for novel therapies.”

Dr. Peter Li,president and chief executive officer of Nexcelom added, “Our team is very excited to be joining forces with PerkinElmer to help scientists resolve some of today’s most pressing health challenges through modernizing cell based assays using the most advanced cell models. Our organization has a deep commitment to innovation and we are looking forward to continuing to grow our technology and customer footprint in combination with PerkinElmer’s strong global presence and infrastructure.”

PerkinElmer’s existing biologics, vaccine and cell and gene research solutions feature industry-leading high content, in vivo, and cell painting screening technologies; innovative immunoassays; CRISPR, RNAi and DNA tools and custom cell lines; cell plate readers and advanced automation; microfluidics and analytical platforms.

The agreement to acquire Nexcelomcomes just five months after PerkinElmer added Horizon Discovery, a leader in gene editing and modulation. To learn more about PerkinElmer’s full range of life sciences solutions, informatics and OneSource services please visit: https://www.perkinelmer.com/corporate/what-we-do/markets/life-sciences.html.

About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

About Nexcelom

Nexcelom Bioscience is a Massachusetts-based developer and marketer of image cytometry products for cell analysis in life science research and drug discovery, development and manufacturing. Products range from high performance cell viability counters (Cellometer and Cellaca) to high throughput microwell image cytometry workstations (Celigo), with turnkey solutions including instruments, consumables and reagents. Founded in 2003 and currently owned by its founders and Ampersand Capital Partners, Nexcelom delivers innovative, fit-for-purpose, accurate cell counting solutions that are critical for advanced therapeutic modalities such as cell and gene therapy. The company currently employs about 130 fast-paced, customer-centric employees who are passionate about making an impact in life science.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our failure to adequately protect our intellectual property; (7) the loss of any of our licenses or licensed rights; (8) our ability to compete effectively; (9) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (10) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (11) disruptions in the supply of raw materials and supplies; (12) the manufacture and sale of products exposing us to product liability claims; (13) our failure to maintain compliance with applicable government regulations; (14) regulatory changes; (15) our failure to comply with healthcare industry regulations; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) significant disruption in our information technology systems, or cybercrime; (19) our ability to obtain future financing; (20) restrictions in our credit agreements; (21) discontinuation or replacement of LIBOR; (22) the United Kingdom’s withdrawal from the European Union; (23) our ability to realize the full value of our intangible assets; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Media Contact:

Jennifer McNeil

PerkinElmer, Inc.

[email protected]

+1 508.380.2902

Investor Relations:

Steve Willoughby

PerkinElmer, Inc.

[email protected]

+1 781.663.5677

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Medical Devices Health Genetics Pharmaceutical

MEDIA:

Logo
Logo

Shift Triples Revenue & Ecommerce Unit Sales in Q1’2021, Raises Guidance for 2021

  • Achieved record revenue and units sold levels in the first quarter; year-over-year growth of 254% and 181%, respectively
  • Grew GPU to $1,655 and Adjusted GPU1 to $1,690, representing sequential quarter-over-quarter growth of 255% and 229%, respectively
  • Projecting 285% year-over-year Q2’2021 revenue growth, at the midpoint of management guidance range

SAN FRANCISCO, May 12, 2021 (GLOBE NEWSWIRE) — Shift Technologies, Inc. (Nasdaq: SFT), a leading end-to-end ecommerce platform for buying and selling used cars, today reported first quarter financial results for the period ended March 31, 2021. Management’s commentary on first quarter financial results and second quarter and full year 2021 outlook can be found by accessing the Company’s shareholder letter on investors.shift.com, or by listening to today’s conference call. A live audio webcast will also be available on Shift’s Investor Relations website.

“In the first quarter we delivered extraordinary revenue growth, more than triple last year’s level, including strong sequential growth quarter over quarter. We also tripled our e-commerce unit sales, while keeping our margins strong,” said Co-CEO and Co-Founder Toby Russell. “We achieved these record results with focused execution on our business plan, rapid growth in our reconditioning throughput, and continued investment in differentiated technology, coupled with a new marketing strategy that we implemented in mid-February. Given this trajectory, we are excited about driving strong performance as the year progresses.”

“For revenue and units sold, our results represent 181% and 254% year-over-year growth, respectively. We achieved Q1 Adjusted GPU1 of $1,690, more than triple Q4’2020 results. We believe this momentum will continue throughout 2021, and our guidance reflects this outlook,” added Shift’s CFO, Oded Shein. “For the second quarter 2021, we expect revenue to grow 13% – 23% sequentially from Q1’2021 and Adjusted GPU1,2 to increase 18% – 30% sequentially from Q1’2021. For the full-year 2021, we expect revenue to grow 145% – 166% over 2020 and Adjusted GPU1,2 to grow 33% year-over-year.”

Q1’2021 Operating Results

All comparisons for the quarter are year-over-year unless otherwise specified.

  • Total revenue grew 254% year-over-year, reaching a record $106.0 million.
  • Total units sold were 5,979, up 181%. Total ecommerce units sold were 4,452 and total wholesale units sold were 1,527, an increase of 213% and 116%, respectively.
  • Gross profit grew to $7.4 million or 6.9% of total revenue, up from $3.3 million. Non-GAAP adjusted gross profit1 grew to $7.5 million or 7.1% of total revenue.
  • Gross profit per unit was $1,655, growing 255% from $466 in Q4’2020.
  • Adjusted gross profit per unit1 (“Adjusted GPU”) was $1,690, growing 229% from $514 in Q4’2020.
  • SG&A was $50.2 million, or 47.4% of revenue, as compared to $13.4 million or 44.9% of revenue.
  • Marketing expenses were $15.4 million, or 14.5% of revenue, as compared to $1.8 million, or 6.0% of revenue.
  • Net loss was $42.8 million as compared to net loss of $12.3 million, and basic and diluted net loss per share was $(0.55) based on 77.9 million weighted average shares outstanding during Q1’2021.
  • Adjusted EBITDA1 was a loss of $34.4 million or 32.5% of total revenue, as compared to a loss of $9.7 million or 32.3% of revenue in the prior year period.

Recent Business Highlights

  • Launched Austin-San Antonio buyer market, marking Shift’s first direct-to-consumer market in Texas
  • Launched seller market for certain vehicles, understood as purchasing cars from sellers, in Las Vegas
  • Saw strong momentum from national brand awareness campaign, which launched in Q1’2021

Shift’s Co-CEO George Arison commented, “Our top-line performance this quarter reflects the strong consumer demand for the easy, differentiated car-buying experience that Shift offers, and our Adjusted GPU1 reflects our ability to meet this demand in an operationally efficient manner. We believe there is still massive opportunity to grow as the car-buying market becomes increasingly digital, and we look forward to bringing the Shift experience to many more consumers.”

Q2’2021 Outlook

We are providing guidance for the quarter ending June 30, 2021 as follows:

  • Revenue in the range of $120 – $130 million, an increase of 270% – 301%, year-over-year
  • Adjusted GPU1,2 in the range of $2,000 – $2,200
  • Adjusted EBITDA1,2 of $(28) – $(31) million

FY 2021 Outlook

We are raising guidance for the year ending December 31, 2021 as follows:

  • Revenue in the range of $480 – $520 million, an increase of 145% – 166% year-over-year
  • Ecommerce units of 21,000 – 23,000
  • Adjusted GPU1,2 greater than $1,800 per ecommerce unit
  • Adjusted EBITDA Margin1,2 better than (24)%

_________________________________________________
____________

1
Adjusted gross
profit
,
Adjusted GPU
,
Adjusted EBITDA
,
and Adjusted EBITDA margin
are non-GAAP financial measures. Please see the discussion in the section “Non-GAAP Financial Measures” and the reconciliations included at the end of this press release.  
2 Specific quantifications of the amounts that would be required to reconcile the company’s adjusted EBITDA and adjusted gross profit per unit guidance are not available. The company believes that there is uncertainty and unpredictability with respect to certain of its GAAP measures, primarily related to adjustments for the valuation of financial instruments that may be required to reconcile to GAAP net loss and GAAP gross profit per unit, which preclude the company from providing accurate guidance on certain forward-looking GAAP to non-GAAP reconciliations. The company believes that providing estimates of the amounts that would be required to reconcile the range of the company’s adjusted EBITDA and adjusted gross profit per unit would imply a degree of precision that would be confusing or misleading to investors for the reasons identified above.



Shift First Quarter 2021 Results Summary                                                                       

  Three Months Ended March 31,
  2021   2020   Change (%)
 
(in thousands, except per unit and per share amounts)
Revenue $ 106,004     $ 29,953     254 %
Gross profit 7,366     3,343     120 %
Adjusted gross profit 7,525     3,502     115 %
Net loss (42,755 )   (12,331 )   247 %
Net loss per share, basic and diluted (0.55 )   (3.84 )   (86 )%
Adjusted EBITDA loss (34,434 )   (9,677 )   256 %
           
Gross profit per unit $ 1,655     $ 2,353     (30 )%
Adjusted gross profit per unit $ 1,690     $ 2,464     (31 )%
Ecommerce average selling price per unit $ 19,981     $ 15,423     30 %
Ecommerce units sold 4,452     1,421     213 %

Conference Call Information

Shift senior management will host a conference call today to discuss the Company’s Q1’2021 financial results and second quarter outlook. This call is scheduled to begin at 2:00 pm PT / 5:00 pm ET and can be accessed by dialing (833) 614-1395 or (914) 987-7116. To listen to a live audio webcast, please visit Shift’s Investor Relations website at investors.shift.com. A replay of the audio webcast will be available on the same website following the call through May 19, 2021. A telephonic replay will be available through May 19, 2021 by dialing (855) 859-2056 or (404) 537-3406 and entering passcode 2789261#.

About Shift

Shift is a leading end-to-end auto ecommerce platform transforming the used car industry with a technology-driven, hassle-free customer experience. Shift’s mission is to make car purchase and ownership simple — to make buying or selling a used car fun, fair, and accessible to everyone. Shift provides comprehensive, digital solutions throughout the car ownership lifecycle: finding the right car, having a test drive brought to you before buying the car, a seamless digitally-driven purchase transaction including financing and vehicle protection products, an efficient, digital trade-in/sale transaction, and a vision to provide high-value support services during car ownership. For more information, visit www.shift.com. The contents of our website are not incorporated into this press release.

Forward-Looking Statements

This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of Shift’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: (1) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, Shift’s ability to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (2) costs related to the business combination; (3) changes in applicable laws or regulations; (4) the possibility that Shift may be adversely affected by other economic, business, and/or competitive factors; (5) the operational and financial outlook of Shift; (6) the ability for Shift to execute its growth strategy; (7) Shift’s ability to purchase sufficient quantities of vehicles at attractive prices; and (8) other risks and uncertainties indicated from time to time in other documents filed or to be filed with the SEC by Shift. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Shift undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Key Operating Metrics

Ecommerce Units Sold

We define ecommerce units sold as the number of vehicles sold to customers in a given period, net of returns. We currently have a seven-day, 200 mile return policy. The number of ecommerce units sold is the primary driver of our revenues and, indirectly, gross profit, since ecommerce unit sales enable multiple complementary revenue streams, including all financing and protection products. We view ecommerce units sold as a key measure of our growth, as growth in this metric is an indicator of our ability to successfully scale our operations while maintaining product integrity and customer satisfaction.

Wholesale Units Sold

We define wholesale units sold as the number of vehicles sold through wholesale channels in a given period. While wholesale units are not the primary driver of revenue or gross profit, wholesale is a valuable channel as it allows us to be able to purchase vehicles regardless of condition, which is important for the purpose of accepting a trade-in from a customer making a vehicle purchase from us, and as an online destination for consumers to sell their cars even if not selling us a car that meetings our retail standards.

Ecommerce Average Sale Price

We define ecommerce average sale price (“ASP”) as the average price paid by a customer for an ecommerce vehicle, calculated as ecommerce revenue divided by ecommerce units. Ecommerce average sale price helps us gauge market demand in real-time and allows us to maintain a range of inventory that most accurately reflects the overall price spectrum of used vehicle sales in the market.

Wholesale Average Sale Price

We define wholesale average sale price as the average price paid by a customer for a wholesale vehicle, calculated as wholesale revenue divided by wholesale units. We believe this metric provides transparency and is comparable to our peers.

Average Monthly Unique Visitors

We define a monthly unique visitor as an individual who has visited our website within a calendar month, based on data collected on our website. We calculate average monthly unique visitors as the sum of monthly unique visitors in a given period, divided by the number of months in that period. To classify whether a visitor is “unique”, we dedupe (a technique for eliminating duplicate copies of repeating data) each visitor based on email address and phone number, if available, and if not, we use the anonymous ID which lives in each user’s internet cookies. This practice ensures that we do not double-count individuals who visit our website multiple times within a month. We view average monthly unique visitors as a key indicator of the strength of our brand, the effectiveness of our advertising and merchandising campaigns and consumer awareness.

Average Days to Sale

We define average days to sale as the number of days between Shift’s acquisition of a vehicle and sale of that vehicle to a customer, averaged across all ecommerce units sold in a period. We view average days to sale as a useful metric in understanding the health of our inventory.

Ecommerce Vehicles Available for Sale

We define ecommerce vehicles available for sale as the number of ecommerce vehicles in inventory on the last day of a given reporting period. Until we reach an optimal pooled inventory level, we view ecommerce vehicles available for sale as a key measure of our growth. Growth in ecommerce vehicles available for sale increases the selection of vehicles available to consumers, which we believe will allow us to increase the number of vehicles we sell. Moreover, growth in ecommerce vehicles available for sale is an indicator of our ability to scale our vehicle purchasing, inspection and reconditioning operations.

Number of Regional Hubs

We define a Hub as a physical location at which we store and recondition units bought and sold within a market. Because of our omni-channel fulfillment model with our on-demand delivery test drive offering, we are able to service super-regional areas covering approximately a 60-mile radius from a single Hub location. This is a key metric as each Hub expands our service area as our service area, reconditioning and storage capacity.

Non-GAAP Financial Measures

In addition to our GAAP results, we review certain non-GAAP financial measures to help us evaluate our business, measure our performance, identify trends affecting our business, establish budgets, measure the effectiveness of investments in our technology and sales and marketing, and assess our operational efficiencies. These non-GAAP measures include adjusted gross profit, adjusted gross profit per unit (“Adjusted GPU”), and Adjusted EBITDA, each of which is discussed below.

These non-GAAP financial measures are not intended to be considered in isolation from, as substitutes for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. You are encouraged to evaluate these adjustments, and review the reconciliation of these non-GAAP financial measures to their most comparable GAAP measures, and the reasons we consider them appropriate. It is important to note that the particular items we exclude from, or include in, our non-GAAP financial measures may differ from the items excluded from, or included in, similar non-GAAP financial measures used by other companies. See “Reconciliation of gross profit to Adjusted Gross Profit,” “Reconciliation of gross profit per unit to Adjusted gross profit per unit” and “Reconciliation of net loss to Adjusted EBITDA” included as part of this press release.

Adjusted Gross Profit:

Management evaluates our business based on an adjusted gross profit calculation that removes the financial impact associated with milestones achieved under our Lithia warrant arrangement, which resulted in reductions in gross profit in our consolidated financial statements as applicable to the periods presented. This is a non-cash adjustment, and we do not expect any material future non-cash gross profit adjustments related to the Lithia warrant agreement. Due to the non-recurring nature of the Lithia warrant agreement, our management believes it to be appropriate to adjust gross profit but these amounts to calculate adjusted gross profit. We examine adjusted gross profit in the aggregate as well as for each of our revenue streams: ecommerce, other, and wholesale.

Adjusted Gross Profit per Unit:

We define adjusted gross profit per unit (“Adjusted GPU”) as the adjusted gross profit for ecommerce, other and wholesale, each of which divided by the total number of ecommerce units sold in the period. Adjusted GPU is driven by ecommerce vehicle revenue, which generates additional revenue through attachment of our financing and protection products, and gross profit generated from wholesale vehicle sales. We present Adjusted GPU from our three revenues streams, as ecommerce Adjusted GPU, Wholesale Adjusted GPU and Other Adjusted GPU. We believe Adjusted GPU is a key measure of our growth
and long-term profitability.   

Adjusted EBITDA and Adjusted EBITDA Margin:

We define Adjusted EBITDA as net loss adjusted to exclude stock-based compensation expense, depreciation and amortization, net interest income or expense, impact of warrant remeasurement, warrant milestone impact, and other cash and non-cash based income or expenses that we do not consider indicative of our core operating performance, including, but not limited to acquisition and related items. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by revenue. We believe Adjusted EBITDA is useful to investors in evaluating our performance for the following reasons:

  • Adjusted EBITDA is widely used by investors and securities analysts to measure a company’s performance without regard to items such as those we exclude in calculating this measure, which can vary substantially from company to company depending upon their financing, capital structures, and the method by which assets were acquired.
  • Our management uses Adjusted EBITDA in conjunction with GAAP financial measures for planning purposes, including the preparation of our annual operating budget, as a measure of performance and the effectiveness of our business strategies, and in communications with our board of directors concerning our performance.
  • Adjusted EBITDA provides a measure of consistency and comparability with our past performance that many investors find useful, facilitates period-to-period comparisons of operations, and also facilitates comparisons with other peer companies, many of which use similar non-GAAP financial measures to supplement their GAAP results.

Although Adjusted EBITDA is frequently used by investors and securities analysts in their evaluations of companies, Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our results of operations as reported under GAAP. These limitations include:

  • Stock-based compensation is a non-cash charge and will remain an element of our long-term incentive compensation package, although we exclude it as an expense when evaluating our ongoing operating performance for a particular period.
  • Depreciation and amortization are non-cash charges, and the assets being depreciated or amortized will often have to be replaced in the future, but Adjusted EBITDA does not reflect any cash requirements for these replacements.
  • Change in fair value of financial instruments is a non-cash gain or loss. Liability-classified financial instruments represent potential future obligations to settle liabilities by issuing the Company’s common stock. Adjusted EBITDA does not reflect changes in the fair value of these obligations.
  • Adjusted EBITDA does not reflect changes in our working capital needs, capital expenditures, or contractual commitments.
  • Adjusted EBITDA does not reflect cash requirements for income taxes and the cash impact of other income or expense.
  • Other companies may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

Our Adjusted EBITDA is influenced by fluctuations in our revenue and the timing and amounts of our investments in our operations. Adjusted EBITDA should not be considered as an alternative to net income (loss), income (loss) from operations, or any other measure of financial performance calculated and presented in accordance with GAAP.

Investor Relations Contact:

Drew Haroldson, The Blueshirt Group
[email protected]

Media Contact:

Jeff Fox, The Blueshirt Group
[email protected]

Source: Shift Technologies, Inc.

SHIFT TECHNOLOGIES, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets


(in thousands, except share and per share amounts)



(unaudited)

  As of March 31, 2021   As of December 31, 2020
ASSETS      
Current assets:      
Cash and cash equivalents $ 176,985     $ 233,936  
Accounts receivable, net 21,208     8,426  
Inventory 74,253     49,086  
Prepaid expenses and other current assets 9,607     5,478  
Total current assets 282,053     296,926  
Property and equipment, net 3,440     2,123  
Capitalized website and internal use software costs, net 7,207     6,542  
Restricted cash, non-current 1,730     1,605  
Deferred borrowing costs 1,391     2,149  
Other non-current assets 2,331     2,748  
Total assets $ 298,152     $ 312,093  
       
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current liabilities:      
Accounts payable $ 12,906     $ 10,675  
Accrued expenses and other current liabilities 25,170     22,286  
Flooring line of credit 31,343     13,870  
Total current liabilities 69,419     46,831  
Financial instruments liability 23,077     25,230  
Other non-current liabilities 3,018     2,850  
Total liabilities 95,514     74,911  
       
Commitment and contingencies      
       
Stockholders’ equity:      
Preferred stock – par value $0.0001 per share; 1,000,000 shares authorized at March 31, 2021 and December 31, 2020, respectively      
Common stock – par value $0.0001 per share; 500,000,000 shares authorized at March 31, 2021 and December 31, 2020, respectively; 84,136,987 and 83,904,182 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively 8     8  
Additional paid-in capital 519,828     511,617  
Accumulated deficit (317,198 )   (274,443 )
Total stockholders’ equity 202,638     237,182  
Total liabilities and stockholders’ equity $ 298,152     $ 312,093  



SHIFT TECHNOLOGIES INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss


(in thousands, except share and per share amounts)



(unaudited)

  Three Months Ended

March 31,
  2021   2020
Revenue      
Ecommerce revenue, net $ 88,954     $ 21,916  
Other revenue 4,019     683  
Wholesale vehicle revenue 13,031     7,354  
Total revenue 106,004     29,953  
Cost of sales 98,638     26,610  
Gross profit 7,366     3,343  
Operating expenses:      
Selling, general and administrative expenses 50,234     13,446  
Depreciation and amortization 1,101     982  
Total operating expenses 51,335     14,428  
Loss from operations (43,969 )   (11,085 )
Change in fair value of financial instruments 2,153      
Interest and other expense, net (939 )   (1,246 )
Net loss and comprehensive loss attributable to common stockholders $ (42,755 )   $ (12,331 )
Net loss and comprehensive loss per share attributable to common stockholders, basic and diluted $ (0.55 )   $ (3.84 )
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted 77,909,110     3,214,113  



SHIFT TECHNOLOGIES INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows


(in thousands)



(unaudited)

  Three Months Ended

March 31,
  2021   2020
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $ (42,755 )   $ (12,331 )
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 1,173     982  
Stock-based compensation expense 8,203     267  
Change in fair value of financial instruments (2,153 )    
Contra-revenue associated with milestones 159     159  
Amortization of debt discount     1,092  
Changes in operating assets and liabilities:      
Accounts receivable (12,782 )   (618 )
Inventory (25,167 )   (3,537 )
Prepaid expenses and other current assets (4,129 )   (534 )
Other non-current assets 296     130  
Accounts payable 1,760     1,309  
Accrued expenses and other current liabilities 3,005     2,160  
Other non-current liabilities 915     (17 )
     Net cash, cash equivalents, and restricted cash used in operating activities (71,475 )   (10,938 )
       
CASH FLOWS FROM INVESTING ACTIVITIES      
Purchases of property and equipment (1,135 )   (168 )
Capitalized website internal-use software costs (1,353 )   (1,103 )
     Net cash, cash equivalents, and restricted cash used in investing activities (2,488 )   (1,271 )
       
CASH FLOWS FROM FINANCING ACTIVITIES      
Proceeds from flooring line of credit facility 57,096     8,103  
Repayment of flooring line of credit facility (39,661 )   (10,380 )
Exchange of warrants for cash (497 )    
Proceeds from stock option exercises, including from early exercised options 200     59  
Repurchase of shares related to early exercised options (1 )    
      Net cash, cash equivalents, and restricted cash provided by (used in) financing activities 17,137     (2,218 )
Net decrease in cash, cash equivalents and restricted cash (56,826 )   (14,427 )
Cash, cash equivalents and restricted cash, beginning of period 235,541     44,576  
Cash, cash equivalents and restricted cash, end of period $ 178,715     $ 30,149  
       
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION      
Cash paid for interest $ 176     $ 287  
       
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES      
Vesting of exercised options $ 132     $ 41  
Stock-based compensation capitalized to internal-use software $ 172     $ 60  



SHIFT TECHNOLOGIES, INC. AND SUBSIDIARIES

Key Operating Metrics


(unaudited)

    Three Months Ended March 31,
    2021   2020
Units:        
Ecommerce units   4,452     1,421  
Wholesale units   1,527     706  
Total units sold   5,979     2,127  
         
Ecommerce ASP   $ 19,981     $ 15,423  
Wholesale ASP   $ 8,534     $ 10,417  
         
Gross Profit per Unit        
Ecommerce Gross Profit per Unit   $ 723     $ 847  
Other Gross Profit per Unit   903     481  
Wholesale Gross Profit per Unit   29     1,025  
Total Gross Profit per Unit   $ 1,655     $ 2,353  
         
Adjusted GPU

1
       
Ecommerce Adjusted GPU   $ 723     $ 847  
Other Adjusted GPU   938     592  
Wholesale Adjusted GPU   29     1,025  
Total Adjusted GPU   $ 1,690     $ 2,464  
         
Average monthly unique visitors   709,409     219,691  
Average days to sale   47     70  
Ecommerce vehicles available for sale   3,736     1,401  
# of regional hubs   6     5  

__________________________________________
1 Adjusted gross profit and Adjusted GPU are non-GAAP financial measures. Please see the discussion in the section “Non-GAAP Financial Measures” and the reconciliations included at the end of this press release.



SHIFT TECHNOLOGIES, INC. AND SUBSIDIARIES

Reconciliation of Gross Profit to Adjusted Gross Profit

(In thousands)

(unaudited)

  Three Months Ended March 31,
  2021   2020
Total gross profit:      
GAAP total gross profit $ 7,366     $ 3,343  
Warrant impact adjustment (1) 159     159  
Adjusted total gross profit $ 7,525     $ 3,502  
       
Ecommerce gross profit:      
GAAP ecommerce gross profit $ 3,217     $ 1,204  
Warrant impact adjustment (1)      
Adjusted ecommerce gross profit $ 3,217     $ 1,204  
       
Other gross profit:      
GAAP other gross profit $ 4,019     $ 683  
Warrant impact adjustment (1) 159     159  
Adjusted other gross profit $ 4,178     $ 842  
       
Wholesale gross profit:      
GAAP wholesale gross profit $ 130     $ 1,456  
Warrant impact adjustment (1)      
Adjusted wholesale gross profit $ 130     $ 1,456  

(1) Includes non-cash charges related to the Lithia warrants and recorded as contra-revenue on the consolidated statements of operations and comprehensive loss.

SHIFT TECHNOLOGIES, INC. AND SUBSIDIARIES

Reconciliation of Gross Profit Per Unit To Adjusted Gross Profit Per Unit

(unaudited)

  Three Months Ended March 31,
  2021   2020
  ($ per ecommerce unit)
Total gross profit per unit:      
GAAP total gross profit per unit $ 1,655     $ 2,353  
Warrant impact adjustment(1) per unit 35     111  
Adjusted total gross profit per unit $ 1,690     $ 2,464  
       
Ecommerce gross profit per unit:      
GAAP ecommerce gross profit per unit $ 723     $ 847  
Warrant impact adjustment(1) per unit      
Adjusted ecommerce gross profit per unit $ 723     $ 847  
       
Other gross profit per unit:      
GAAP other gross profit per unit $ 903     $ 481  
Warrant impact adjustment(1) per unit 35     111  
Adjusted other gross profit per unit $ 938     $ 592  
       
Wholesale gross profit per unit:      
GAAP wholesale gross profit per unit $ 29     $ 1,025  
Warrant impact adjustment(1) per unit      
Adjusted wholesale gross profit per unit $ 29     $ 1,025  

(1) Includes non-cash charges related to the Lithia warrants and recorded as contra-revenue on the consolidated statements of operations and comprehensive loss.

SHIFT TECHNOLOGIES, INC. AND SUBSIDIARIES

Reconciliation of Net Loss to Adjusted EBITDA

(In thousands)

(unaudited)

  Three Months Ended March 31,
  2021   2020

Adjusted EBITDA Reconciliation
     
Net Loss $ (42,755 )   $ (12,331 )
(+) Interest and other expense, net 939     1,246  
(+) Stock-based compensation 8,203     267  
(+) Change in fair value of financial instruments (2,153 )    
(+) Depreciation & amortization 1,173     982  
(+) Contra-revenue associated with milestones (1) 159     159  
Adjusted EBITDA $ (34,434 )   $ (9,677 )
Adjusted EBITDA Margin (%) (32.5 )%   (32.3 )%

(1) Includes non-cash charges related to the Lithia warrants and recorded as contra-revenue on the consolidated statements of operations and comprehensive loss.



Amwell® Announces Results for First Quarter 2021

Amwell® Announces Results for First Quarter 2021

  • Total active providers of approximately 81,000 at the end of the first quarter increased 240% compared to a year ago
  • Total visits of 1.6 million in the first quarter increased 120% compared to a year ago
  • Total visits since inception surpassed 10 million in the first quarter with 5.9 million added in 2020
  • Revenue of $57.6 million in the first quarter increased 7% over COVID enhanced volume first quarter last year

BOSTON–(BUSINESS WIRE)–Amwell®, (NYSE: AMWL) (the “Company”) a national telehealth leader, today announced financial results for the first quarter ended March 31, 2021.

“Our first quarter results represent a strong start to the year and demonstrate continued momentum across our business.

As telehealth evolved from a complimentary service to a fundamental enabler of mainstream healthcare, we too have advanced our innovation and investment strategy: our next generation platform Converge is designed to enable healthcare’s most trusted players to carry out digitally empowered, full-spectrum, unified online and in-person care. At its core, we believe Converge offers exceptional usability, reliability, scalability and flexibility. With its modular open architecture and longitudinal capabilities, we believe Converge will simplify innovative collaboration across the ecosystem. We expect Converge to expand our market opportunity and enhance our own efficiencies over time. We also expect it to accelerate innovators’ ability to impact clinical and financial outcomes by creating a faster path to implement new technologies and services in a single integrated platform,” said Dr. Ido Schoenberg, Chairman and Co-CEO.

First quarter 2021 Financial Highlights:

All comparisons, unless otherwise noted, are to the three months ended March 31, 2020.

  • Total active providers grew to ~81,000, compared to ~24,000 last year and ~72,000 last quarter
  • Total visits were ~1.6 million, compared to ~725,000

    • Amwell Medical Group (“AMG”) visits were 20% of total visits, compared to 50% of total visits
  • Total visits since inception surpassed 10 million in the first quarter with 5.9 million added in 2020
  • Total Revenue was $57.6 million, compared to $53.7 million

    • Subscription revenue was $24.6 million, compared to $21.8 million
    • Visit revenue was $27.8 million, compared to $26.5 million
  • Gross margin was 38.0%, compared to 38.5%
  • Net loss was $39.8 million, compared to $25.2 million
  • Adjusted EBITDA was $(26.4) million, compared to $(17.7) million, as a result of increased R&D investment in the Converge technology platform

Financial Outlook

For 2021, the company reiterates their previous outlook of:

  • Revenue between $260 and $270 million
  • AMG visit volume between 1.5 and 1.7 million
  • Adjusted EBITDA between ($157) million and ($147) million

Quarterly Conference Call Details

The company will host a conference call to review the results today, Wednesday, May 12, 2021 at 5:00 p.m. E.T. to discuss its financial results. The call can be accessed via a line audio webcast at https://investors.amwell.com or by dialing 1-833-979-2840 for U.S. participants, or 1-263-384-2051 for international participants, referencing conference ID #4793448. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Amwell

Amwell is a leading telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 2,000 hospitals and over 55 health plan partners with over 36,000 employers, covering over 80 million lives. For more information please visit https://business.amwell.com/.

American Well, Amwell, Converge and Amwell Medical Group are registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our beliefs and assumptions only as of the date of this release. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: weak growth and increased volatility in the telehealth market; inability to adapt to rapid technological changes; increased competition from existing and potential new participants in the healthcare industry; changes in healthcare laws, regulations or trends and our ability to operate in the heavily regulated healthcare industry; our ability to comply with federal and state privacy regulations; the significant liability that could result from a cybersecurity breach; and other factors described under ‘Risk Factors’ in our most recent form 10-K filed with the SEC. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission. These filings, when available, are available on the investor relations section of our website at investors.amwell.com and on the SEC’s website at www.sec.gov.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

March 31,

2021

 

 

December 31,

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

896,382

 

 

$

941,616

 

Investments

 

 

99,997

 

 

 

99,963

 

Restricted cash

 

 

795

 

 

 

1,095

 

Accounts receivable ($1,182 and $12,053, from related parties and net of allowances of $1,514 and $1,556, respectively)

 

 

37,679

 

 

 

45,296

 

Inventories

 

 

9,366

 

 

 

9,128

 

Deferred contract acquisition costs

 

 

2,205

 

 

 

2,134

 

Prepaid expenses and other current assets

 

 

14,882

 

 

 

14,055

 

Total current assets

 

 

1,061,306

 

 

 

1,113,287

 

Property and equipment, net

 

 

3,383

 

 

 

3,836

 

Goodwill

 

 

193,877

 

 

 

193,877

 

Intangible assets, net

 

 

53,600

 

 

 

55,528

 

Operating lease right-of-use asset

 

 

4,999

 

 

 

6,609

 

Deferred contract acquisition costs, net of current portion

 

 

1,124

 

 

 

1,327

 

Other assets

 

 

1,391

 

 

 

1,430

 

Investment in minority owned joint venture

 

 

2,481

 

 

 

752

 

Total assets

 

$

1,322,161

 

 

$

1,376,646

 

Liabilities, Convertible Preferred Stock and Stockholders’ Deficit

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,797

 

 

$

5,797

 

Accrued expenses and other current liabilities

 

 

23,386

 

 

 

42,135

 

Operating lease liability, current

 

 

4,931

 

 

 

6,357

 

Deferred revenue ($3,176 and $14,421 from related parties, respectively)

 

 

63,202

 

 

 

66,693

 

Total current liabilities

 

 

98,316

 

 

 

120,982

 

Other long-term liabilities

 

 

45

 

 

 

64

 

Operating lease liability, net of current portion

 

 

970

 

 

 

1,296

 

Deferred revenue, net of current portion ($32 and $486 from related parties, respectively)

 

 

7,455

 

 

 

8,107

 

Total liabilities

 

 

106,786

 

 

 

130,449

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ deficit:

 

 

 

 

 

 

 

 

Preferred stock

 

 

 

 

 

 

Common stock

 

 

2,396

 

 

 

2,357

 

Treasury stock

 

 

 

 

 

(37,568

)

Additional paid-in capital

 

 

1,860,123

 

 

 

1,841,405

 

Accumulated other comprehensive income

 

 

279

 

 

 

297

 

Accumulated deficit

 

 

(668,871

)

 

 

(582,359

)

Total American Well Corporation stockholders’ equity

 

 

1,193,927

 

 

 

1,224,132

 

Non-controlling interest

 

 

21,448

 

 

 

22,065

 

Total stockholders’ equity

 

 

1,215,375

 

 

 

1,246,197

 

Total liabilities, preferred stock and stockholders’ equity

 

$

1,322,161

 

 

$

1,376,646

 

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Revenue

 

 

 

 

 

 

 

 

($8,845 and $13,248 from related parties, respectively)

 

$

57,599

 

 

$

53,714

 

Costs and operating expenses:

 

 

 

 

 

 

 

 

Costs of revenue, excluding depreciation and amortization of intangible assets

 

 

35,705

 

 

 

33,027

 

Research and development

 

 

23,040

 

 

 

14,936

 

Sales and marketing

 

 

13,732

 

 

 

13,874

 

General and administrative

 

 

21,354

 

 

 

15,342

 

Depreciation and amortization expense

 

 

2,506

 

 

 

2,286

 

Total costs and operating expenses

 

 

96,337

 

 

 

79,465

 

Loss from operations

 

 

(38,738

)

 

 

(25,751

)

Interest income and other income (expense), net

 

 

61

 

 

 

847

 

Loss before expense from income taxes and loss from equity method investment

 

 

(38,677

)

 

 

(24,904

)

Expense from income taxes

 

 

(309

)

 

 

 

Loss from equity method investment

 

 

(819

)

 

 

(320

)

Net loss

 

 

(39,805

)

 

 

(25,224

)

Net loss attributable to non-controlling interest

 

 

(617

)

 

 

(843

)

Net loss attributable to American Well Corporation

 

$

(39,188

)

 

$

(24,381

)

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.16

)

 

$

(0.58

)

Weighted-average common shares outstanding, basic and diluted

 

 

243,544,647

 

 

 

42,383,251

 

Net loss

 

$

(39,805

)

 

$

(25,224

)

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

 

 

Unrealized gain on available-for-sale investments

 

 

34

 

 

 

43

 

Foreign currency translation

 

 

(52

)

 

 

(171

)

Comprehensive loss

 

 

(39,823

)

 

 

(25,352

)

Less: Comprehensive loss attributable to non-controlling interest

 

 

(617

)

 

 

(843

)

Comprehensive loss attributable to American Well Corporation

 

$

(39,206

)

 

$

(24,509

)

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(39,805

)

 

$

(25,224

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization expense

 

 

2,506

 

 

 

2,286

 

Provisions for doubtful accounts

 

 

260

 

 

 

165

 

Amortization of deferred contract acquisition costs

 

 

335

 

 

 

271

 

Amortization of deferred contract fulfillment costs

 

 

173

 

 

 

168

 

Stock-based compensation expense

 

 

8,642

 

 

 

4,458

 

Loss on equity method investment

 

 

819

 

 

 

320

 

Changes in operating assets and liabilities, net of acquisition:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

7,357

 

 

 

(1,710

)

Inventories

 

 

(238

)

 

 

(612

)

Deferred contract acquisition costs

 

 

(203

)

 

 

(458

)

Prepaid expenses and other current assets

 

 

(167

)

 

 

(2,401

)

Other assets

 

 

39

 

 

 

(355

)

Accounts payable

 

 

1,023

 

 

 

(45

)

Accrued expenses and other current liabilities

 

 

(17,666

)

 

 

(4,922

)

Other long-term liabilities

 

 

(19

)

 

 

(254

)

Deferred revenue

 

 

(4,195

)

 

 

(3,780

)

Net cash used in operating activities

 

 

(41,139

)

 

 

(32,093

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(148

)

 

 

(1,254

)

Investment in less than majority owned joint venture

 

 

(2,548

)

 

 

(2,940

)

Purchases of investments

 

 

 

 

 

(29,777

)

Proceeds from sales and maturities of investments

 

 

 

 

 

39,611

 

Net cash (used in) provided by investing activities

 

 

(2,696

)

 

 

5,640

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from issuance of Series C convertible preferred stock, net of issuance costs

 

 

 

 

 

12,564

 

Proceeds from exercise of common stock options

 

 

9,297

 

 

 

2

 

Payments for the purchase of treasury stock

 

 

(9,383

)

 

 

 

Payment of deferred offering costs

 

 

(1,613

)

 

 

 

Net cash (used in) provided by financing activities

 

 

(1,699

)

 

 

12,566

 

Net decrease in cash, cash equivalents, and restricted cash

 

 

(45,534

)

 

 

(13,887

)

Cash, cash equivalents, and restricted cash at beginning of period

 

 

942,711

 

 

 

138,816

 

Cash, cash equivalents, and restricted cash at end of period

 

$

897,177

 

 

$

124,929

 

Cash, cash equivalents, and restricted cash at end of period:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

896,382

 

 

 

123,834

 

Restricted cash

 

 

795

 

 

 

1,095

 

Total cash, cash equivalents, and restricted cash at end of period

 

$

897,177

 

 

$

124,929

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

Cash paid for income taxes

 

$

741

 

 

$

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Additions to property and equipment included in accrued expenses and accounts payable

 

$

23

 

 

$

 

Exercises of common stock

 

$

833

 

 

$

 

Repurchase of common stock

 

$

388

 

 

$

 

Common stock issuance costs

 

$

 

 

$

143

 

 

Non-GAAP Financial Measures:

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, of US GAAP, we use adjusted EBITDA, which is a non-U.S GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of adjusted EBITDA enhances an investor’s understanding of our financial performance. We further believe that adjusted EBITDA is a useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as the primary measure of our performance.

We calculate adjusted EBITDA as net loss adjusted to exclude (i) interest income and other income, net, (ii) tax benefit and expense, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) public offering expenses, (vi) acquisition-related income and expenses, (vii) litigation expenses related to the defense of our patents in the patent infringement claim filed by Teladoc and (viii) other items affecting our results that we do not view as representative of our ongoing operations, including direct and incremental expenses associated with the COVID-19 pandemic.

We believe adjusted EBITDA is a commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss, loss per share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.

Adjusted EBITDA has important limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of the limitations of adjusted EBITDA include (i) adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these capital expenditures. Our IPO and acquisition-related expenses, including legal, accounting and other professional expenses, reflect cash expenditures and we expect such expenditures for acquisitions to recur from time to time. Our adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure.

In evaluating adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered as an alternative to loss before benefit from income taxes, net loss, earnings per share, or any other performance measures derived in accordance with U.S. GAAP. When evaluating our performance, you should consider adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.

Other than with respect to GAAP Revenue, the Company only provides guidance on a non-GAAP basis. The Company does not provide a reconciliation of forward-looking Adjusted EBITDA (non-GAAP) to GAAP net income (loss), due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation because other deductions (such as COVID expenses and acquisition related expenses) used to calculate projected net income (loss) vary dramatically based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income (loss) at this time. The amount of these deductions may be material and, therefore, could result in projected GAAP net income (loss) being materially less than projected Adjusted EBITDA (non-GAAP).

The following table presents a reconciliation of adjusted EBITDA from the most comparable GAAP measure, net loss, for the three months ended March 31, 2021 and 2020:

 

 

Three Months Ended

March 31,

 

(in thousands)

 

2021

 

 

2020

 

Net loss

 

$

(39,805

)

 

$

(25,224

)

Add:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

2,506

 

 

 

2,286

 

Interest income and other income (expense), net

 

 

(61

)

 

 

(847

)

Expense from income taxes

 

 

309

 

 

 

 

Stock-based compensation

 

 

8,642

 

 

 

4,458

 

Public offering expenses

 

 

1,223

 

 

 

151

 

Acquisition-related income

 

 

 

 

 

17

 

COVID-19-related expenses(1)

 

 

 

 

 

1,413

 

Litigation expense

 

 

739

 

 

 

 

Adjusted EBITDA

 

$

(26,447

)

 

$

(17,746

)

(1)

 

COVID-19-related expenses include non-recurring provider bonus payments, emergency hosting licensing fees and non-medical provider temporary labor costs related to on-boarding non-AMG providers incurred in response to the initial outbreak of the COVID-19 virus as Amwell attempted to scale quickly to meet unusually high patient and non-AMG provider demand.

(2)

 

Public offering expenses include non-recurring expenses incurred in relation to our initial public offering for the three months ended March 31, 2020 and our secondary offering for the three months ended March 31, 2021.

 

Media Contact:

Holly Spring

[email protected]

781.888.8219

Investor Contact:

Asher Dewhurst

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Software Practice Management Managed Care General Health Health Data Management Hospitals Technology

MEDIA:

Great Lakes Dredge & Dock Corporation Announces Pricing of Senior Notes

Higher-Interest Senior Notes to be Redeemed with Net Proceeds

HOUSTON, May 12, 2021 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (NASDAQ: GLDD) (“Great Lakes” or the “Company”) announced today that it has agreed to sell $325 million aggregate principal amount of its unsecured 5.25% Senior Notes due 2029 (the “2029 Notes”) pursuant to its previously-announced private offering.

The 2029 Notes were priced to investors at par and will mature on June 1, 2029. Each of the Company’s existing and future wholly-owned domestic subsidiaries that are co-borrowers or guarantors under its senior secured revolving credit agreement will guarantee the 2029 Notes.

Great Lakes intends to use the net proceeds from the offering, together with cash on hand, to redeem all $325 million aggregate principal amount of its outstanding 8.000% Senior Notes due 2022. The offering is expected to be completed on May 25, 2021, subject to the satisfaction or waiver of customary closing conditions.

The 2029 Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws in the United States and may not be offered or sold in the United States absent registration or an exemption from the applicable registration requirements. Accordingly, the 2029 Notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A promulgated under the Securities Act and to non-U.S. persons outside the United States in accordance with Regulation S promulgated under the Securities Act. Holders of the 2029 Notes will not have registration rights.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, the 2029 Notes, nor will there be any sale of the 2029 Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute a notice of redemption with respect to any of the Company’s outstanding senior notes.


The Company

Great Lakes is the largest provider of dredging services in the United States. In addition, the Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 130-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of over 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident & Injury Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.


Cautionary Note Regarding Forward-Looking Statements

Except for historical and factual information, the matters set forth in this release and other of our oral or written statements identified by words such as “intends,” “plans,” “expects,” “anticipates,” “believes” and “will” and similar expressions are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Great Lakes and its subsidiaries, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These cautionary statements are being made with the intention of obtaining the benefits of the “safe harbor” provisions of the federal securities laws. Great Lakes cautions investors that any forward-looking statements made by Great Lakes are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to Great Lakes, include, but are not limited to: our failure to satisfy the conditions to the initial purchasers’ obligation to consummate the offering; corporate developments that could preclude, impair or delay the above-described transactions due to restrictions under the federal securities laws; changes in the Company’s credit ratings; changes in the cash requirements, financial position, financing plans or investment plans of the Company or its affiliates; changes in general market, economic, tax, regulatory or industry conditions that impact the ability or willingness of the Company or its affiliates to consummate the above-described transactions on the terms described above or at all; and other risks referenced from time to time in the filings of the Company with the SEC.

Although Great Lakes believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any forward-looking statements. Great Lakes’ future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. The forward-looking statements contained in this press release are made only as of the date hereof and Great Lakes does not have or undertake any obligation to publicly update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

For further information contact:

Tina Baginskis

Director, Investor Relations

630-574-3024



Dicerna to Participate in Upcoming Investor Conferences

Dicerna to Participate in Upcoming Investor Conferences

LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences:

  • RBC Capital Markets Global Healthcare Conference,fireside chat on Wednesday, May 19 at 10:20 a.m. ET.
  • Oppenheimer Rare & Orphan Disease Summit, presentation available on Friday, May 21 at 8:00 a.m. ET.

Audio webcasts of the fireside chat and presentation will be accessible from the “Investors and Media” section of the Dicerna website at investors.dicerna.com. Archived replays will be available on the Company’s website following the events.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna’s GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of our flagship liver-targeted GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world’s leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. At Dicerna, our mission is to interfere – to silence genes, to fight disease, to restore health. For more information, please visit www.dicerna.com.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements pertaining to the Company’s planned participation at investor conferences, which may include discussion of the Company’s business and operations, including the discovery, development and commercialization of our product candidates and technologies, and the therapeutic potential thereof, the success of our collaborations with partners and any potential future collaborations. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and clinical programs and other risks identified under the heading “Risk Factors” included in our most recent Form 10-Q and Form 10-K filings and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna’s current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

GalXC™ and GalXC-Plus™ are trademarks of Dicerna Pharmaceuticals, Inc.

Media:

Amy Trevvett

+1 617-612-6253

[email protected]

Investors:

Janhavi Mohite

+1 212-362-1200

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Other Science Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo

Amdocs acquires Sourced to Further Boost Communications Industry’s Move to the Cloud

Deal expands Amdocs’ portfolio of market-leading cloud-native products and services; brings Sourced’s decade-long experience of delivering cloud at scale

ST. LOUIS, May 12, 2021 (GLOBE NEWSWIRE) — Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today announced it has acquired Sourced Group, a leading global technology consultancy specializing in large-scale cloud transformations for sophisticated, high-end enterprises in industries such as financial services, communications and others. The two companies are excited by the opportunity to strengthen Amdocs’ capabilities for taking the communications industry to the cloud and bring to Amdocs’ 350+ service provider customers Sourced’s decade-long experience of delivering cloud at scale.

“We are delighted the innovative Sourced team is joining Amdocs. We are proud to bring such great professionals and practices to our industry and look forward to working with their wide-reaching customer base in North America, Asia-Pacific and Australia. This acquisition is part of our wider cross-company investment in the cloud and will further solidify our leadership in this domain as we accelerate our strategy to take the communications and media industry to the cloud,” said Shuky Sheffer, President and Chief Executive Officer of Amdocs Management Limited. “Sourced’s proven cloud migration platform, deployment framework and trusted design process, alongside its deep partnerships with Amazon Web Services, Microsoft Azure and Google Cloud Platform, complement our portfolio of cloud-native products and services and further expands and diversifies our customer base.”

“We are excited to join Amdocs and believe the combination of Amdocs’ cloud-native products and services and our high-end consulting and deep expertise across the entire cloud transformation process will prove compelling for service providers as they move to the cloud,” said Jon Spinks, Sourced founder and CEO. “We also look forward to continuing serving our current customers and leveraging Amdocs’ scale to further accelerate their cloud journeys.”

Sourced, a previously privately-owned company headquartered in Toronto, has offices in Australia, Singapore and Malaysia.

Amdocs acquired Source in mid-March for a net consideration of approximately $75 million in cash1. Additional consideration may be paid later based on the achievement of certain performance metrics. The impact of the acquisition on Amdocs’ non-GAAP diluted earnings per share2 is expected to be neutral in the full fiscal year 2021. The impact on GAAP diluted earnings per share will not be known until after Amdocs completes the purchase price allocation.

_____________________________
1 A net consideration of approximately $65 million was paid in the second fiscal quarter of fiscal 2021, while the remaining amount is expected to be paid in the third quarter of fiscal 2021
2 Non-GAAP diluted earnings per share excludes amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisitions related liabilities measured at fair value, equity-based compensation expenses, gain from divestiture of OpenMarket and other, net of related tax effects



Supporting Resources

About Amdocs

Amdocs’ purpose is to enrich lives and progress society, using creativity and technology to build a better connected world. Amdocs and its 27,000 employees partner with the leading players in the communications and media industry, enabling next-generation experiences in 85 countries. Our cloud-native, open and dynamic portfolio of digital solutions, platforms and services brings greater choice, faster time to market and flexibility, to better meet the evolving needs of our customers as they drive growth, transform and take their business to the cloud. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $4.2 billion in fiscal 2020. For more information, visit Amdocs at www.amdocs.com.

Amdocs’ Forward-Looking Statement

This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs’ growth and business results in future quarters. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general economic conditions, the duration and severity of the COVID-19 pandemic, and its impact on the global economy, Amdocs’ ability to grow in the business markets that it serves, Amdocs’ ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company’s products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, the Company specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs’ filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2020 filed on December 14, 2020, and our Form 6-K furnished for the first quarter of fiscal 2021 filed on February 16, 2021.

Media Contacts:

Jeff Barak
Amdocs Public Relations
Tel: +972 52 645 3637
E-mail: [email protected]

Emily Holt
PAN Communications for Amdocs
Email: [email protected]